Myriad to Perform BRCA Companion Dx Testing for BioMarin's PARP Inhibitor BMN 673

BioMarin is developing BMN 673 for genetically defined cancers. Myriad will apply its BRACAnalysis test in clinical trials for BioMarin to determine if patients have BRCA1 and BRCA2 mutations and therefore should receive the PARP inhibitor.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.